Literature DB >> 35122025

Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression.

Zoila A Lopez-Bujanda1,2,3, Michael C Haffner1,4, Matthew G Chaimowitz2, Nivedita Chowdhury1,2, Nicholas J Venturini2, Radhika A Patel4, Aleksandar Obradovic2, Corey S Hansen5, Joanna Jacków5,6, Janielle P Maynard1, Karen S Sfanos1,7,8, Cory Abate-Shen9,10,11,12, Charles J Bieberich13,14, Paula J Hurley7,15, Mark J Selby16,17, Alan J Korman16,18, Angela M Christiano5,19, Angelo M De Marzo1,7,8, Charles G Drake20,21,22.   

Abstract

Unlike several other tumor types, prostate cancer rarely responds to immune checkpoint blockade (ICB). To define tumor cell intrinsic factors that contribute to prostate cancer progression and resistance to ICB, we analyzed prostate cancer epithelial cells from castration-sensitive and -resistant samples using implanted tumors, cell lines, transgenic models and human tissue. We found that castration resulted in increased expression of interleukin-8 (IL-8) and its probable murine homolog Cxcl15 in prostate epithelial cells. We showed that these chemokines drove subsequent intratumoral infiltration of tumor-promoting polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), which was largely abrogated when IL-8 signaling was blocked genetically or pharmacologically. Targeting IL-8 signaling in combination with ICB delayed the onset of castration resistance and increased the density of polyfunctional CD8 T cells in tumors. Our findings establish a novel mechanism by which castration mediates IL-8 secretion and subsequent PMN-MDSC infiltration, and highlight blockade of the IL-8/CXCR2 axis as a potential therapeutic intervention.
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 35122025      PMCID: PMC9169571          DOI: 10.1038/s43018-021-00227-3

Source DB:  PubMed          Journal:  Nat Cancer        ISSN: 2662-1347


  46 in total

1.  VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.

Authors:  Jianjun Gao; John F Ward; Curtis A Pettaway; Lewis Z Shi; Sumit K Subudhi; Luis M Vence; Hao Zhao; Jianfeng Chen; Hong Chen; Eleni Efstathiou; Patricia Troncoso; James P Allison; Christopher J Logothetis; Ignacio I Wistuba; Manuel A Sepulveda; Jingjing Sun; Jennifer Wargo; Jorge Blando; Padmanee Sharma
Journal:  Nat Med       Date:  2017-03-27       Impact factor: 53.440

2.  Nuclear factor-kappa B is essential for up-regulation of interleukin-8 expression in human amnion and cervical epithelial cells.

Authors:  C L Elliott; V C Allport; J A Loudon; G D Wu; P R Bennett
Journal:  Mol Hum Reprod       Date:  2001-08       Impact factor: 4.025

Review 3.  Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies.

Authors:  Zoila Lopez-Bujanda; Charles G Drake
Journal:  J Leukoc Biol       Date:  2017-05-26       Impact factor: 4.962

4.  The prognostic landscape of genes and infiltrating immune cells across human cancers.

Authors:  Andrew J Gentles; Aaron M Newman; Chih Long Liu; Scott V Bratman; Weiguo Feng; Dongkyoon Kim; Viswam S Nair; Yue Xu; Amanda Khuong; Chuong D Hoang; Maximilian Diehn; Robert B West; Sylvia K Plevritis; Ash A Alizadeh
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

5.  ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.

Authors:  Alvaro Aytes; Antonina Mitrofanova; Carolyn Waugh Kinkade; Celine Lefebvre; Ming Lei; Vanessa Phelan; H Carl LeKaye; Jason A Koutcher; Robert D Cardiff; Andrea Califano; Michael M Shen; Cory Abate-Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-05       Impact factor: 11.205

6.  TGM4: an immunogenic prostate-restricted antigen.

Authors:  Zoila A Lopez-Bujanda; Aleksandar Obradovic; Thomas R Nirschl; Laura Crowley; Rodney Macedo; Alexandros Papachristodoulou; Timothy O'Donnell; Uri Laserson; Jelani C Zarif; Ran Reshef; Tiezheng Yuan; Mithil K Soni; Emmanuel S Antonarakis; Michael C Haffner; H Benjamin Larman; Michael M Shen; Pawel Muranski; Charles G Drake
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

7.  Tracking single cells in live animals using a photoconvertible near-infrared cell membrane label.

Authors:  Alicia L Carlson; Joji Fujisaki; Juwell Wu; Judith M Runnels; Raphaël Turcotte; Joel A Spencer; Cristina Lo Celso; David T Scadden; Terry B Strom; Charles P Lin
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

8.  Effective combinatorial immunotherapy for castration-resistant prostate cancer.

Authors:  Xin Lu; James W Horner; Erin Paul; Xiaoying Shang; Patricia Troncoso; Pingna Deng; Shan Jiang; Qing Chang; Denise J Spring; Padmanee Sharma; John A Zebala; Dean Y Maeda; Y Alan Wang; Ronald A DePinho
Journal:  Nature       Date:  2017-03-20       Impact factor: 49.962

9.  Robust antigen-specific CD8 T cell tolerance to a model prostate cancer neoantigen.

Authors:  Zoila A Lopez-Bujanda; Matthew G Chaimowitz; Todd D Armstrong; Jeremy B Foote; Leisha A Emens; Charles G Drake
Journal:  Oncoimmunology       Date:  2020-09-06       Impact factor: 8.110

10.  The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis.

Authors:  Mark M Pomerantz; Fugen Li; David Y Takeda; Romina Lenci; Apurva Chonkar; Matthew Chabot; Paloma Cejas; Francisca Vazquez; Jennifer Cook; Ramesh A Shivdasani; Michaela Bowden; Rosina Lis; William C Hahn; Philip W Kantoff; Myles Brown; Massimo Loda; Henry W Long; Matthew L Freedman
Journal:  Nat Genet       Date:  2015-10-12       Impact factor: 38.330

View more
  6 in total

Review 1.  Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Cell Oncol (Dordr)       Date:  2022-05-19       Impact factor: 7.051

Review 2.  Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer.

Authors:  Arthur Mulvey; Emilien Muggeo-Bertin; Dominik R Berthold; Fernanda G Herrera
Journal:  Front Immunol       Date:  2022-04-28       Impact factor: 8.786

Review 3.  Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer.

Authors:  Izabela Siemińska; Jarek Baran
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

4.  Enhancing immune checkpoint blockade therapy of genitourinary malignancies by co-targeting PMN-MDSCs.

Authors:  Xuemin Lu; Xin Lu
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2022-02-25       Impact factor: 11.414

5.  A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.

Authors:  Landon C Brown; Susan Halabi; Jason A Somarelli; Michael Humeniuk; Yuan Wu; Taofik Oyekunle; Lauren Howard; Jiaoti Huang; Monika Anand; Catrin Davies; Prekshaben Patel; Janet Staats; Kent J Weinhold; Michael R Harrison; Tian Zhang; Daniel J George; Andrew J Armstrong
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-03-15       Impact factor: 5.455

Review 6.  Checkpoint inhibitor/interleukin-based combination therapy of cancer.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Cancer Med       Date:  2022-03-17       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.